MIC 541-Exam 5-Virology 26

• Combo of 3 antiviral drugs
• Typically 2 Non-nucleosides and 1 nucleoside

• Fusion
• RT
• Integration into host genome
• Maturation

• Nucleoside
• Non-nucleoside
• Protease inhibitors
• Integrase inhibitors
• Fusion inhibitors

• Block maturation
• Inhibit Gag and Gag-Pol protein cleavage

Bind Mg2+ binding pocket and block Integrase processing of viral DNA

Peptide analogs that bind to fusion peptide gp41 and prevent fusion

Atripla

• Quasispecies make a single genetic epitope useless
• Humoral immunity is ineffective
• Inability to design a vaccine that elicits CTL response
• Live attenuated vaccine is unthinkable

Highly mutagenic species

• HIV envelope is heavily glycosylated
• Envelope is also highly variable

• Integration would mean that vaccinated would become carriers
• Over time carriers would gain mutations an live virus would be made
• Recombination could lead to a more pathogenic virus

• DNA vaccines and antigen expressing vectors
• Vaccinate mucosal sites
• Designer envelope proteins that facilitate neutralizing antibodies

Evidence that CD8 T cell response may restrict size of viral founder populations t mucosal surfaces

Difference in placebo and vaccinated group came from the low to medium risk group

• Ineffective
• Found to be somewhat enhancing of infection in African population

• V520 Ad5 recombinant vector designed to elicit CTL response
• Adenovirus expressing HIV proteins

• Circumcision
• Education
• Prophylaxis

• Low dose ART in high risk groups (discordant couples and prostitutes)
• Vaginal and Anal gels

HIV patient that received a bone-marrow transplant from a CCR5-delta32 individual is now HIV free

Truncated 32 AAs for CCR5 co-receptor of HIV

10% of European population